Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38709991.
- Also identified by DOI 10.1200/PO.24.00113.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gong et al present two NCI-MATCH tumor-agnostic trials evaluating erdafitinib for FGFR-altered cancers, marking steppingstones in precision oncology.
Medical subject headings
- Mutation
- Neoplasms
- Quinoxalines
- Receptors, Fibroblast Growth Factor